A detailed history of Xtx Topco LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Xtx Topco LTD holds 7,191 shares of BGNE stock, worth $1.28 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
7,191
Holding current value
$1.28 Million
% of portfolio
0.12%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $1.04 Million - $1.61 Million
7,191 New
7,191 $1.61 Million
Q4 2023

Feb 13, 2024

BUY
$158.67 - $201.58 $216,743 - $275,358
1,366 New
1,366 $246,000
Q2 2023

Aug 14, 2023

BUY
$178.3 - $266.78 $213,960 - $320,135
1,200 New
1,200 $213,000
Q3 2021

Nov 12, 2021

SELL
$249.6 - $403.14 $332,966 - $537,788
-1,334 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$292.75 - $367.01 $390,528 - $489,591
1,334 New
1,334 $458,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.